Skip to content
Screener

G&A at other companies

Janux Therapeutics logo
Janux TherapeuticsJANX
$10.96M+4.9%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$26.2M+85.4%
Immix Biopharma, Inc. logo
Immix Biopharma, Inc.IMMX
$4.82M+78.1%
Xenon Pharmaceuticals logo
Xenon PharmaceuticalsXENE
$23.93M+24.4%
Sutro Biopharma logo
Sutro BiopharmaSTRO
$7.58M-42.9%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$8.1M+54.5%

Other financials

Income statement

See full
Revenue$51.2M+17.5%
Operating income-$37.1M-11.7%
Net income-$21.7M+29.5%
EPS (diluted)-$0.29+29.3%

Balance sheet

See full
Cash & equivalents$44.7M+0.5%
Total debt$170.1M-20.1%
Total equity$503.2M-18.9%
Total assets$725.0M-17.6%

Cash flow

See full
Operating cash flow-$55.7M-53.0%
CapEx$538.0K+40.5%
Free cash flow-$56.2M-52.9%

Valuation

See full
Market cap$1.55B+221%
Enterprise value$1.67B+159%
P/S14.7×+11.5×

Profitability

See full
Operating margin-205.8%-2,501pp
Net margin-155.6%+78.8pp
FCF margin-198.4%-1,485pp

Returns & leverage

See full
Return on equity-29.1%+0.2pp
Debt / equity0.3×0.0×
Current ratio6.4×+1.1×

Where this comes from

Reported directly by Xencor in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Xencor’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:02 PM EDT
Fiscal quarter
Q4 FY2028
Calendar quarter
Q4 2028
Accession
0001326732-26-000056
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Collaborations, milestones, and royalties$51,221$43,608$55,737$76,340
Operating expenses:
Research and development71,90561,665136,574120,243
General and administrative16,38415,11534,09332,452
Total operating expenses88,28976,780170,667152,695
Operating loss(37,068)(33,172)(114,930)(76,355)
Other income (expense):
Interest income4,8007,24810,25914,786

Item 1. Financial Statements

FAQ

What is Xencor's G&A?
Xencor (XNCR) reported G&A of $16.38M in Q2 2026.
How has Xencor's G&A changed year-over-year?
Xencor's G&A increased by 8.4% year-over-year, from $15.12M to $16.38M.
What is the long-term trend for Xencor's G&A?
Over 4 years (2021 to 2025), Xencor's G&A has grown at a 13.1% compound annual growth rate (CAGR), from $38.84M to $63.64M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Xencor's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude